Is it necessary to continue taking brigatinib without interruption?

Brigatinib (also known as Brigatinib) is an oral ALKtyrosine kinase inhibitor, mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). The use of this type of targeted drug usually requires continuous administration, because it is not a one-time curative drug, but slows down the progression of the disease and controls the condition by inhibiting mutation driver genes in tumor cells. In most cases, doctors will recommend that patients continue to use brigatinib as long as the disease does not progress and no serious side effects occur.

If a patient interrupts brigatinib while taking it, it may cause a drop in blood drug concentration, thereby weakening the ability to control cancer cells and giving the tumor a chance to grow again or progress. Some studies have shown that sudden discontinuation or discontinuation of treatment may lead to a rapid rebound of the disease, especially in the early stages when the tumor has not yet been completely controlled. Therefore, it is generally not recommended that patients stop medication or interrupt treatment without authorization, especially without communicating with their doctor.

However, in some special circumstances, such as the occurrence of serious adverse reactions or the need for other interventional treatments (such as surgery or other combined diseases), doctors may evaluate whether it is necessary to temporarily discontinue the drug or adjust the dose based on the specific circumstances. The discontinuation of medication at this time is planned and controllable, and treatment will be gradually resumed under follow-up monitoring. If patients feel unwell, they must communicate with their attending physician as soon as possible instead of reducing the dose or discontinuing the medication on their own.

In short, the brigatinib treatment process emphasizes the principle of "continuous and stable" medication. Long-term and regular use is an important prerequisite for maximizing the effectiveness of the medicine. Patients should review regularly during the medication period to evaluate the efficacy and side effects, adjust the treatment plan according to the doctor's recommendations, and do not interrupt medication due to symptom relief or side effects, so as not to affect the treatment results.

Reference: https://go.drugbank.com/drugs/